Advertisement

Cell-Mediated Interactions of Advanced Glycosylation End Products and the Vascular Wall

  • Helen Vlassara
Part of the Clinical Physiology Series book series (CLINPHY)

Abstract

Thickening of the arterial wall in atherosclerosis is associated with abnormal basement membrane and subintimal collagen deposition, and the focal proliferation of vascular smooth muscle cells leads to an increase in peripheral resistance. Related events include increases in endothelial cell permeability and leakage, and the deposition of serum proteins, such as albumin, cholesterol esters, and fibrin. These pathological changes are believed to contribute to the pathogenesis of both the atherosclerotic and the thrombotic vasculopathies associated with aging and chronic diabetes (1,14,18,28).

Keywords

Endothelial Cell Monolayer Radioreceptor Assay Tissue Factor Activity Advanced Glycosylation Glycation Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bloodworth, J. M. B., JR., and Greider, M. H. Endocrine Pathology, General and Surgical, 2nd ed. Baltimore: Williams and Wilkins, 1982, p. 556.Google Scholar
  2. 2.
    Brownlee, M., Vlassara, H., and Cerami, A. Nonenzymatic glycosylation products on collagen covalently trap low density lipoprotein. Diabetes 34: 938–941, 1985.PubMedCrossRefGoogle Scholar
  3. 3.
    Brownlee, M., Vlassara, H., and Cerami, A. Trapped immunoglobulins on peripheral nerve myelin from patients with diabetes mellitus. Diabetes 35: 999–1003, 1986.PubMedCrossRefGoogle Scholar
  4. 4.
    Brownlee, M., Cerami, A., and Vlassara, H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318: 1315 1321, 1988.Google Scholar
  5. 5.
    Brownlee, M., Pongor, S., and Cerami, A. Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen: role in the in situ formation of immune complexes. J. Exp. Med. 158: 1739–1744, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Brownlee, M., Cerami, A., and Vlassara, H. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes/Metab. Rev. 4: 437–451, 1988.CrossRefGoogle Scholar
  7. 7.
    Brownlee, M., Vlassara, H., and Cerami, A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann. Intern. Med. 101: 527–537, 1984.PubMedCrossRefGoogle Scholar
  8. 8.
    Brownlee, M., Vlassara, H., and Cerami, A. The pathogenetic role of nonenzymatic glycosylation in diabetic complications. In Diabetic Complications: Scientific and Clinical Aspects, edited by M. J. C. Crabbe. London: Pitman, pp. 94–139, 1987.Google Scholar
  9. 9.
    Bunn, H. F., Gabbay, K. H., and Gallop, P. M. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200: 21–27, 1978.PubMedCrossRefGoogle Scholar
  10. 10.
    Cerami, A., Vlassara, H., and Brownlee, M. Role of nonenzymatic glycosylation in atherogenesis. In Perspectives in Inflammation, Neoplasia and Vascular Cell Biology. Proceedings of The UCLA Symposia on Molecular and Cellular Biology, edited by T. Edgington, R. Ross, and S. Silverstein. New York: Alan R. Liss, pp. 105–114, 1986. J. Cell. Biochem. 30: 111–120, 1986.Google Scholar
  11. 11.
    Esmon, C. The regulation of natural anticoagulant pathways. Science 235: 1348–1352, 1987.PubMedCrossRefGoogle Scholar
  12. 12.
    Esposito, C., Gerlach, H., Brett, J., Stern, D., and Vlassara, H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased mono-layer permeability and modulation of cell surface coagulant properties. J. Exp. Med. 170: 1387–1407, 1989.PubMedCrossRefGoogle Scholar
  13. 13.
    Farmar, J. G., Ulrich, P. C., and Cerami, A. Novel pyrroles from sulfite-inhibited Maillard reactions: insight into the mechanism of inhibition. J. Organic Chem. 53: 2346 2349, 1988.Google Scholar
  14. 14.
    Fleg, J. L. Alterations in cardiovascular structure and function with advancing age. Am. J. Cardiol. 57: 33C - 44C, 1986.CrossRefGoogle Scholar
  15. 15.
    Froesch, E. R., Schmid, Chr., Schwander, J., and Zapf, J. Actions of insulin-like growth factors. Annu. Rev. Physiol. 47: 443–467, 1985.PubMedCrossRefGoogle Scholar
  16. 16.
    Gerrity, R. G. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am. J. Pathol. 103: 181–190, 1981.PubMedGoogle Scholar
  17. 17.
    Gimbrone, M. (ed). Vascular Endothelium in Hemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1986.Google Scholar
  18. 18.
    Greene, D. A. Acute and chronic complications of diabetes mellitus in older patients. Am. J. Med. 80 (5A): 39–53, 1986.CrossRefGoogle Scholar
  19. 19.
    Harrison, D., and Vlassara, H. Receptor-mediated binding of advanced glycosylation endproducts to murine macrophages: effects on aging. (submitted).Google Scholar
  20. 20.
    Hayase, F., Nagaraj, R. H., Miyata, S., Njoroge, F. G., and Monnier, V. M. Aging of proteins immunological detection of a glucose derived pyrrole formed during Maillard reaction in vivo. J. Biol. Chem. 264: 3758–3764, 1989.PubMedGoogle Scholar
  21. 21.
    Kirstein, M., Brett, J., Radoff, S., Ogawa, S., Stern, D., and Vlassara, H. Advanced protein glycosylation induces selective transendothelial human monocyte chemotaxis and secretion of Pdgf: role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. USA 87: 9010–9014, 1990.PubMedCrossRefGoogle Scholar
  22. 22.
    Kirstein, M., Aston, C., and Vlassara, H. Normal human monocytes express insulin-like growth factor-1 (Igf-1) in response to matrix glycation: role in tissue remodelling. Faseb J. 4: A1759, 1990.Google Scholar
  23. 23.
    Koenig, R. J., and Cerami, A. Synthesis of hemoglobin Ali in normal and diabetic mice: potential model of basement membrane thickening. Proc. Natl. Acad. Sci. USA 72: 3587–3691, 1975.Google Scholar
  24. 24.
    Le, J. M., Weinstein, D., Gubler, U., and Vilcek, J. Induction of membrane-associated interleukin by tumor necrosis factor in human fibroblasts. J. Immunol. 138: 2137 2142, 1987.Google Scholar
  25. 25.
    Makita, Z., Radoff, S., Rayfield, E. J., Yang, Z., Skolnik, E., Friedman, E. A., Cerami, A., and Vlassara, H. Advanced glycosylation endproducts in patients with diabetic nephropathy. N. Eng. J. Med. 325: 836–842, 1991.CrossRefGoogle Scholar
  26. 26.
    Monnier, V. M., Vishwanath, V., Frank, K. E., Elmets, C. A., Dauchot, P., and Kohn, R. R. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N. Engl. J. Med. 314: 403–408, 1986.PubMedCrossRefGoogle Scholar
  27. 27.
    Monnier, V. M., Kohn, R., R., and Cerami, A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Natl. Acad. Sci. USA 81: 583–587, 1984.PubMedCrossRefGoogle Scholar
  28. 28.
    National Diabetes Data Group. Diabetes in America. Washington, DC: U.S. Government Printing Office, Nih Publication No. 85–1468, 1985.Google Scholar
  29. 29.
    Njorge, F. G., Fernandes, A. A., and Monnier, V. M. Mechanism of formation of the putative advanced glycosylation endproduct and protein crosslink 2-(2-furoyl)-4(5)(2-furanyl)-1H-imidazole. J. Biol. Chem. 263: 10646–10652, 1988.Google Scholar
  30. 30.
    Njoroge, F. G., Sayre, L. M., and Monnier, V. M. Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohydr. Res. 167: 211–220, 1987.PubMedCrossRefGoogle Scholar
  31. 31.
    Oimomi, M., Maeda, Y., Hata, F., Ketamura, Y., Matsumoto, S., Hatanaka, H., and Baba, S. A study of the age-related acceleration of glycation of tissue protein in rats. J. Gerontol. 43: B98–101, 1988.PubMedCrossRefGoogle Scholar
  32. 32.
    Pongor, S., Ulrich, P. C., Bencsath, F. A., and Cerami, A. Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc. Natl. Acad. Sci. USA 81: 2684–2688, 1984.PubMedCrossRefGoogle Scholar
  33. 33.
    Radoff, S., Vlassara, H., and Cerami, A. Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified non-enzymatically by advanced glycosylated endproducts. Arch. Biochem. Biophys. 263: 418–423, 1988.PubMedCrossRefGoogle Scholar
  34. 34.
    Radoff, S., Cerami, A., and Vlassara, H. Isolation of a surface binding protein specific for advanced glycosylation endproducts from the murine macrophage-derived cell line Raw 264.7. Diabetes 39: 1510–1518, 1990.PubMedCrossRefGoogle Scholar
  35. 35.
    Reynolds, T. M. Chemistry of nonenzymatic browning. Adv. Food Res. 12: 1–52, 1963.PubMedCrossRefGoogle Scholar
  36. 36.
    Ross, R., and Glomset, J. A. The pathogenesis of atherosclerosis. N. Engl. J. Med. 295: 369–377, 1976.PubMedCrossRefGoogle Scholar
  37. 37.
    Simionescu, M., and Simionescu, N. Endothelial Cell Biology. New York: Plenum Press, 1987.Google Scholar
  38. 38.
    Steinbrecher, U. P., Parthasarathy, S., Leake, D. S., Witztum, J. L., and Steinberg, D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA 81: 3883–3887, 1984.PubMedCrossRefGoogle Scholar
  39. 39.
    Stern, D., and Nawroth, P. (eds). Vessel Wall. Semin. Thromb. Hemostas., 1987.Google Scholar
  40. 40.
    Takata, K., Horiuchi, S., Araki, N., Shiga, M., and Saitoh, M. Endocytic uptake of non-enzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J. Biol. Chem. 263: 14819–14825, 1988.PubMedGoogle Scholar
  41. 41.
    Vlassara, H., Brownlee, M., and Cerami, A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J. Exp. Med. 164: 1301–1309, 1986.PubMedCrossRefGoogle Scholar
  42. 42.
    Vlassara, H., Brownlee, M., and Cerami, A. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc. Natl. Acad. Sci. USA 82: 5588–5592, 1985.PubMedCrossRefGoogle Scholar
  43. 43.
    Vlassara, H., Brownlee, M., and Cerami, A. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J. Exp. Med. 160: 197–207, 1984.PubMedCrossRefGoogle Scholar
  44. 44.
    Vlassara, H., Valinsky, J., Brownlee, M., Cerami, C., Nishimoto, S., and Cerami, A. Advanced glycosylation endproducts on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages: a model for turnover of aging cells. J. Exp. Med. 166: 539–549, 1987.PubMedCrossRefGoogle Scholar
  45. 45.
    Vlassara, H., Brownlee, M., Manoque, K. R., Dinarello, C., and Pasagian, A. Cachectin/ Tnf and IL-1 induced by glucose-modified proteins: role in normal tissue remodelling. Science 240: 1546–1548, 1988.PubMedCrossRefGoogle Scholar
  46. 46.
    Vlassara, H., Brownlee, M., and Cerami, A. Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes 37: 456–461.Google Scholar
  47. 47.
    Vlassara, H., Moldawer, L., and Chan, B. Macrophage/monocyte receptor for non-enzymatically glycosylated proteins is up-regulated by cachectin/tumor necrosis factor. J. Clin. Invest. 84: 1813–1820, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© American Physiological Society 1992

Authors and Affiliations

  • Helen Vlassara

There are no affiliations available

Personalised recommendations